A5050525368- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Galectins and Cancer Biology
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Platelet Disorders and Treatments
- Gastrointestinal Tumor Research and Treatment
- Complement system in diseases
- Toxin Mechanisms and Immunotoxins
- Advanced Breast Cancer Therapies
- Hematopoietic Stem Cell Transplantation
- Blood groups and transfusion
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Acute Lymphoblastic Leukemia research
- Chemotherapy-induced cardiotoxicity and mitigation
- Cutaneous lymphoproliferative disorders research
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Venous Thromboembolism Diagnosis and Management
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
National Heart Lung and Blood Institute
2016-2025
National Institutes of Health
2016-2025
Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease that refractory to immunosuppression, persistent, severe cytopenia a profound deficit in hematopoietic stem cells progenitor cells. Thrombopoietin may increase the number
PURPOSE Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for prognostication and risk-stratification are needed. PATIENTS AND METHODS Patients treated phase II III provided discovery data set were subdivided into internal validation cohorts. An external cohort included 84 patients enrolled our...
Clinical trials of ibrutinib combined with anti-CD20 monoclonal antibodies (mAb) for chronic lymphocytic leukemia (CLL) report encouraging results. Paradoxically, in preclinical studies, vitro was reported to decrease CD20 expression and inhibit cellular effector mechanisms. We therefore set out investigate effects vivo treatment that could explain this paradox.Patients received single-agent (420 mg daily) on an investigator-initiated phase II trial. Serial blood samples were collected...
To determine the role of CD49d for response to Bruton's tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL).In treated acalabrutinib (n=48), expression, VLA-4 integrin activation, and tumor transcriptomes CLL cells were assessed. Clinical responses BTKis investigated (n=48; NCT02337829), ibrutinib (n=73; NCT01500733) patients.In acalabrutinib, treatment induced lymphocytosis was comparable both subgroups but resolved more rapidly CD49d+ cases. Acalabrutinib...
Ibrutinib, a Bruton tyrosine kinase inhibitor, is new targeted agent approved by the US Food and Drug Administration for treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, Waldenström macroglobulinemia. Ibrutinib overall well tolerated but long-term required until disease progression or intolerable toxic effects occur. Little known regarding its cutaneous adverse effects.To describe hair nail manifestations associated with use ibrutinib CLL.Prospective study 66 patients...
Vaccinations effectively prevent infections; however, patients with chronic lymphocytic leukemia (CLL) have reduced antibody responses following vaccinations. Combined humoral and cellular immune to novel adjuvanted vaccines are not well characterized in CLL. In an open-label, single-arm clinical trial, we measured the immunogenicity of recombinant zoster vaccine (RZV) CLL who were treatment naïve (TN) or receiving Bruton tyrosine kinase inhibitor (BTKi) therapy. The primary endpoint was...
Patients receiving lenalidomide are at an increased risk for deep venous thrombosis (DVT). Here, we prospectively investigated the DVT in patients with relapsed chronic lymphocytic leukemia (CLL) treated (n = 32). Five developed six incidents of over 1 year annual incidence 16%. Three these were considered drug-related. Median time to was 105 days (range 56-259 days). No pulmonary embolism detected. Hypercoagulability screen before study entry negative all who subsequently DVTs. Compared...
Abstract Immune stimulation contributes to lenalidomide’s antitumor activity. Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature, autoreactive B cells in secondary lymphoid tissues, blood, and bone marrow progressive immune dysfunction. Previous studies CLL indicated that lenalidomide can repair defective T cell function vitro. Whether activation required for clinical response remains unclear. In this study, we report changes microenvironment patients with...
Immune dysregulation in chronic lymphocytic leukemia (CLL) contributes to a high rate of infections and morbidity. The Bruton tyrosine kinase (BTK) inhibitors ibrutinib acalabrutinib mark major breakthroughs the treatment CLL, however many patients require long-term therapy with these agents. Despite receiving effective for on BTK remain immunocompromised at risk infectious complications. We previously reported that CLL leads partial reconstitution humoral immunity fewer during first two...